Company news

MoonLake Immunotherapeutics news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

November 13, 2022

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

September 25, 2022

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

July 25, 2022

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

May 11, 2022

MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab

October 3, 2021

← Newer news releases

Calls

Decks

The 5 newest of 12 decks. Every deck is listed under its year.